150 related articles for article (PubMed ID: 33048115)
1. Detection of genes responsible for cetuximab sensitization in colorectal cancer cells using CRISPR-Cas9.
Hu TT; Yang JW; Yan Y; Chen YY; Xue HB; Xiang YQ; Ye LC
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33048115
[TBL] [Abstract][Full Text] [Related]
2. Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells.
Park SM; Hwang CY; Cho SH; Lee D; Gong JR; Lee S; Nam S; Cho KH
FEBS J; 2019 Apr; 286(7):1305-1318. PubMed ID: 30719834
[TBL] [Abstract][Full Text] [Related]
3. Lemur tyrosine kinase-3 (LMTK3) induces chemoresistance to cetuximab in colorectal cancer via the ERK/MAPK pathway.
Wang C; Yang M; Gu X; Gu Y
Bioengineered; 2021 Dec; 12(1):6594-6605. PubMed ID: 34516351
[TBL] [Abstract][Full Text] [Related]
4. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
[TBL] [Abstract][Full Text] [Related]
5. New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients.
Jing C; Wang T; Ma R; Cao H; Wang Z; Liu S; Chen D; Zhang J; Wu Y; Zhang Y; Wu J; Feng J
Mol Carcinog; 2020 May; 59(5):478-491. PubMed ID: 32141150
[TBL] [Abstract][Full Text] [Related]
6. Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?
Weinberg BA
J Natl Compr Canc Netw; 2018 Dec; 16(12):1547-1548. PubMed ID: 30545999
[No Abstract] [Full Text] [Related]
7. Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab.
Liu R; Zhao X; Guo W; Huang M; Qiu L; Zhang W; Zhang Z; Li W; Zhu X; Chen Z
Clin Transl Oncol; 2020 Jun; 22(6):928-934. PubMed ID: 31571151
[TBL] [Abstract][Full Text] [Related]
8. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
[TBL] [Abstract][Full Text] [Related]
9. Silencing Smad4 attenuates sensitivity of colorectal cancer cells to cetuximab by promoting epithelial‑mesenchymal transition.
Lin Z; Zhang L; Zhou J; Zheng J
Mol Med Rep; 2019 Oct; 20(4):3735-3745. PubMed ID: 31485652
[TBL] [Abstract][Full Text] [Related]
10. Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer.
Li C; Singh B; Graves-Deal R; Ma H; Starchenko A; Fry WH; Lu Y; Wang Y; Bogatcheva G; Khan MP; Milne GL; Zhao S; Ayers GD; Li N; Hu H; Washington MK; Yeatman TJ; McDonald OG; Liu Q; Coffey RJ
Proc Natl Acad Sci U S A; 2017 Apr; 114(14):E2852-E2861. PubMed ID: 28320945
[TBL] [Abstract][Full Text] [Related]
11.
Ye S; Hu X; Ni C; Jin W; Xu Y; Chang L; Zhou H; Jiang J; Yang L
Mol Cancer Ther; 2020 Mar; 19(3):956-965. PubMed ID: 31924740
[TBL] [Abstract][Full Text] [Related]
12. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer.
Peng K; Liu R; Yu Y; Liang L; Yu S; Xu X; Liu T
Biomed Pharmacother; 2018 Jan; 97():1138-1146. PubMed ID: 29136952
[TBL] [Abstract][Full Text] [Related]
14. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
Zhang H; Yuan L; Liu L; Yan C; Cheng J; Fu Q; Tong Z; Jiang W; Zheng Y; Zhao P; Zhang G; Fang W
BMC Cancer; 2020 May; 20(1):416. PubMed ID: 32404198
[TBL] [Abstract][Full Text] [Related]
15. Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells.
Rodrigues JG; Duarte HO; Gomes C; Balmaña M; Martins ÁM; Hensbergen PJ; de Ru AH; Lima J; Albergaria A; van Veelen PA; Wuhrer M; Gomes J; Reis CA
Cell Oncol (Dordr); 2021 Aug; 44(4):835-850. PubMed ID: 33847896
[TBL] [Abstract][Full Text] [Related]
16. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
Gbenedio OM; Bonnans C; Grun D; Wang CY; Hatch AJ; Mahoney MR; Barras D; Matli M; Miao Y; Garcia KC; Tejpar S; Delorenzi M; Venook AP; Nixon AB; Warren RS; Roose JP; Depeille P
JCI Insight; 2019 Jun; 5(15):. PubMed ID: 31237864
[TBL] [Abstract][Full Text] [Related]
17. UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients.
Cacciola NA; Calabrese C; Malapelle U; Pellino G; De Stefano A; Sepe R; Sgariglia R; Quintavalle C; Federico A; Bianco A; Uchimura Bastos A; Milone M; Bellevicine C; Milone F; Carlomagno C; Selvaggi F; Troncone G; Fusco A; Pallante P
Mol Carcinog; 2016 May; 55(5):793-807. PubMed ID: 25917796
[TBL] [Abstract][Full Text] [Related]
18. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
Weng WH; Leung WH; Pang YJ; Hsu HH
Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ITGB1 enhance the anti-tumor effect of cetuximab in colorectal cancer cell.
Yang X; Wang S; Yu W; Zheng Y; Wu Y
Medicine (Baltimore); 2020 Jul; 99(27):e20944. PubMed ID: 32629699
[TBL] [Abstract][Full Text] [Related]
20. RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.
Li XX; Zheng HT; Peng JJ; Huang LY; Shi DB; Liang L; Cai SJ
Int J Clin Exp Pathol; 2014; 7(5):2729-36. PubMed ID: 24966994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
